Cargando…

CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission

Despite the heterogeneity of acute myeloid leukemia (AML), overexpression of the interleukin-3 receptor-α (CD123) on both the more differentiated leukemic blast and leukemic stem cells (LSCs) provides a therapeutic target for antibody treatment. Here we present data on the potential clinical activit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, L H, Biondo, M, Busfield, S J, Arruda, A, Yang, X, Vairo, G, Minden, M D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520399/ https://www.ncbi.nlm.nih.gov/pubmed/28574487 http://dx.doi.org/10.1038/bcj.2017.52

Ejemplares similares

Adoptive immunotherapy for AML with CD123-engager T cells
por: Bonifant, Challice, et al.
Publicado: (2015)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

A radiolabeled antibody targeting CD123(+) leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML
por: Leyton, Jeffrey V., et al.
Publicado: (2015)

FLT3‐ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression
por: Soare, Dan‐Sebastian, et al.
Publicado: (2020)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

Novel CD123 polyaptamer hydrogel edited by Cas9/sgRNA for AML-targeted therapy
por: Wu, Haibin, et al.
Publicado: (2021)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019)

Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1
por: Ernst, Daniel, et al.
Publicado: (2019)

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms
por: Thiago, Leandro S., et al.
Publicado: (2013)

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
por: Williams, Brent A., et al.
Publicado: (2018)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
por: Jin, Xin, et al.
Publicado: (2023)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models
por: Mu-Mosley, Hong, et al.
Publicado: (2022)

Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96
por: Mohseni Nodehi, Sahar, et al.
Publicado: (2012)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML
por: Yao, Sun, et al.
Publicado: (2019)

A New Kind of Science: NKS 2004 Conference & Minicourse
por: Collective
Publicado: (2004)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo
por: Li, G, et al.
Publicado: (2014)

CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses
por: Monaghan, Katherine A., et al.
Publicado: (2023)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies
por: El Achi, Hanadi, et al.
Publicado: (2020)

Opus 123
por: Arredondo, Inés
Publicado: (1988)

Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones
por: Al-Mawali, Adhra, et al.
Publicado: (2016)

Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic
por: Aref, Salah, et al.
Publicado: (2020)

Clinical Impact of CD25/CD123 Coexpression in Adult B-Cell Acute Lymphoblastic Leukemia Patients
por: Aref, Salah, et al.
Publicado: (2020)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
por: Liu, Fu-rong, et al.
Publicado: (2017)

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2023)

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping
por: Bras, Anne E., et al.
Publicado: (2018)

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020)

Plasmacytoid Dendritic Cell Marker (CD123) Expression in Scarring and Non-scarring Alopecia
por: Krishnamurthy, Suganthi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ls6126p7rpqffdufndmddm1ot